These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 11417446)

  • 21. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
    Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG
    Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity.
    Bathum L; Andersen-Ranberg K; Boldsen J; Brøsen K; Jeune B
    Eur J Clin Pharmacol; 1998 Jul; 54(5):427-30. PubMed ID: 9754988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.
    Kovacs P; Edwards DJ; Lalka D; Scheiwe WM; Stoeckel K
    Ther Drug Monit; 1999 Oct; 21(5):526-31. PubMed ID: 10519449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
    Cho JY; Yu KS; Jang IJ; Yang BH; Shin SG; Yim DS
    Br J Clin Pharmacol; 2002 Apr; 53(4):393-7. PubMed ID: 11966672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
    von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
    J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
    Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
    Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
    Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients.
    Taguchi M; Nozawa T; Mizumaki K; Inoue H; Tahara K; Takesono C; Hashimoto Y
    Biol Pharm Bull; 2004 Oct; 27(10):1642-8. PubMed ID: 15467211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
    Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
    Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
    He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
    Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.
    Gonzalez HM; Romero EM; Peregrina AA; de J Chávez T; Escobar-Islas E; Lozano F; Hoyo-Vadillo C
    J Clin Pharmacol; 2003 Nov; 43(11):1211-5. PubMed ID: 14551175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.